Drug Trial Radar · NCT06393803
Phase 1 Study of KH607 Tablets
Last checked: Nov 19, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
88
Planned (sponsor's estimate)
Start
Oct 21, 2023
Primary completion
Oct 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) stage. The primary objective was to evaluate the safety and tolerability of KH607 tablets in Chinese healthy volunteers.
Conditions
- Healthy
Interventions
2mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose.
5mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose.
10mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose or multiple doses.
20mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose or multiple doses.
30mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose or multiple doses.
40mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose.
50mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose.
60mg KH607 tabletsDrug
Subject receive KH607 tablets or placebo orally single dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-lead ECGsTime frame: Screening up to Part 1 Days, Part 2 Day14.
- Physical ExaminationTime frame: Screening up to Part 1 Days, Part 2 Day14.
- 12-lead ECGsTime frame: Screening up to Part 2 Day14.
- Stanford Sleepiness ScaleTime frame: Screening up to Part 1 Day3,Part 2 Day14.
- Modified Observer's Assessment of Alertness/Sedation scaleTime frame: Screening up to Part 1 Day3,Part 2 Day14.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anding Hospital Affiliated to Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.